Eperisone
Eperisone has been studied in 1 paper since 2025: 1 trial in people. The newest paper, Oct 15, 2025: “Effectiveness of glucosamine hydrochloride and eperisone with exercise therapy on inflammatory factors and knee joint function in patients with knee osteoarthritis”.
“Post-treatment, both groups showed decreased serum MMP-3, TNF-α, and IL-6 levels, with significantly greater reductions in Group B (p < 0.001).”
None of its findings points the other way.
- 1 lab in 1 country
- Human trial1
What did studies of Eperisone find?
4Studies of Eperisone measured 4 outcomes; the most studied are clinical efficacy (1 study), knee joint function (1) and symptom scores (1).
Clinical efficacy
upin humans1
1 study
Clinical efficacy
upin humans1
Eperisone improves clinical efficacy in humans (100.00% vs 86.67%, p = 0.038).
“The effective rate was higher in Group B (100.00%) than in Group A (86.67%) (p = 0.038).”
Human trialcombined with glucosamine hydrochloride and exercise therapy vs glucosamine hydrochloride plus exercise therapyn = 60
Journal of drug targeting
Knee joint function
upin humans1
1 study
Knee joint function
upin humans1
Eperisone improves knee joint function in humans (p < 0.001).
“greater ROM and Lysholm improvements (p < 0.001), and better functional performance (p < 0.001).”
Human trialcombined with glucosamine hydrochloride and exercise therapy vs glucosamine hydrochloride plus exercise therapyn = 60
Journal of drug targeting
Symptom scores
downin humans1
1 study
Symptom scores
downin humans1
Eperisone decreases symptom scores in humans (p < 0.05).
“Group B had lower symptom scores (p < 0.05), greater ROM and Lysholm improvements (p < 0.001), and better functional performance (p < 0.001).”
Human trialcombined with glucosamine hydrochloride and exercise therapy vs glucosamine hydrochloride plus exercise therapyn = 60
Journal of drug targeting
Inflammation
downin humans1
1 study
Inflammation
downin humans1
Eperisone decreases inflammation in humans (p < 0.001).
“Post-treatment, both groups showed decreased serum MMP-3, TNF-α, and IL-6 levels, with significantly greater reductions in Group B (p < 0.001).”
Human trialcombined with glucosamine hydrochloride and exercise therapy vs glucosamine hydrochloride plus exercise therapyserumn = 60
Journal of drug targeting